New nerve block aims to slash opioid use after spine fusion

NCT ID NCT07291388

Recruiting now Symptom relief Sponsor: Pontificia Universidad Catolica de Chile Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 07, 2026 · Updated 3 times

Summary

This study tests whether an ultrasound-guided retrolaminar block (a numbing injection near the spine) can lower the amount of opioids patients need after lumbar spine fusion surgery. Forty-four adults will be randomly assigned to receive either the active block or a sham injection, and all will get standard pain medicines. Researchers will track opioid use, pain scores, and recovery quality for three days after surgery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: retrolaminar block with bupivacaine and epinephrine
What this could lead to: If it works, this could offer a way to reduce opioid use and improve pain control after spine surgery.
What could go wrong: This is a small, early-stage trial with only 44 participants. The sham group may also show benefits, and results may not apply to all spine surgeries.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE PAIN are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Acute Pain ankylosis lumbar disk disease vertebral column disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE PAIN ANESTHESIA LUMBAR SPINE DISEASE

Contacts and locations

Locations

Hospital Clínico Pontificia Universidad Católica de Chile
RECRUITING

Santiago, Santiago Metropolitan, Chile

More trials for these conditions

Other studies related to the condition(s) this trial covers.